Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside.
Cytosine arabinoside (Ara-C) treatment of peripheral blood mononuclear cells from 12/12 chronic-phase chronic myelogenous leukaemia (CML) patients revealed a proliferative response stimulated by their untreated leukaemic cells. Specific recognition of tumour cells by patients' normal lymphocytes was suggested by the finding that cells of siblings genotypically identical for human leukocyte antigen caused no stimulation. Lymphocytes thus stimulated by tumour cells from one of these patients were cloned by limiting dilution and tested for antileukaemic effects in cytotoxicity and proliferation assays. Cytotoxic lines were isolated that killed autologous CML targets but only a limited number of allogeneic fresh leukaemias or cell lines. These results show that anti-leukaemia effectors can be isolated from chronic-phase CML patients and suggest their potential application in adoptive immunotherapy.
Pawelec
G
G
Immunology Laboratory, Medizinische Klinik, Tübingen, Federal Republik of Germany.
Schmidt
H
H
Rehbein
A
A
Busch
F
F
D000943:Antigens, Differentiation / Q000032:analysis; D003561:Cytarabine / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000943:Antigens, Differentiation; D007376:Interleukin-2; D003561:Cytarabine